A concerning trend has emerged where prescription weight-loss drugs, including Mounjaro and Wegovy, are being illicitly traded among women, often referred to as "Mounjaro Mums." These medications, officially classified as GLP-1 receptor agonists, are intended for individuals with specific health criteria, such as a high body mass index (BMI).
However, a growing number of individuals who do not medically qualify for these prescriptions are obtaining them through informal networks, frequently involving other mothers met at school gates, gyms, or social gatherings. This practice bypasses essential health screenings and medical oversight, posing significant risks.
The availability of both injectable pens and newer pill forms of these drugs has facilitated their circulation. Some individuals who initially obtained the medication through legitimate channels, such as online pharmacies, may stockpile extra doses. As these supplies approach their expiration dates, or as newer pill formulations become available and more convenient, they may offer these surplus medications to friends and acquaintances to recoup costs.
Health and Safety Concerns
Trading these prescription medications outside of medical supervision is both ill-advised and illegal. While some may feel reassured by obtaining the actual medication from a known source rather than potentially counterfeit versions sold online, the risks remain substantial. Without proper medical screening, individuals may use these drugs despite contraindications, such as a history of disordered eating or specific health issues like thyroid, gallbladder, kidney, or pancreatic problems, which could be exacerbated by GLP-1 use.
Concerns have also been raised about the dosage. In one instance, a woman reportedly received a 15mg Mounjaro pen, the maximum dose, without the recommended gradual dose titration. This could lead to severe side effects or adverse reactions, particularly if the user is unaware of the risks or fails to disclose their medication use to healthcare providers.
Furthermore, the use of GLP-1 medications can impact medical procedures. These drugs delay gastric emptying, meaning patients may have undigested food in their stomach even when fasting. This can increase the risk of pulmonary aspiration during surgery, a serious complication where stomach contents enter the lungs, potentially leading to severe pneumonia or respiratory failure. A delay in an urgent hysterectomy for one individual was reportedly caused by her undisclosed use of Wegovy.
Financial and Insurance Implications
Individuals using these drugs without proper prescription may also face financial repercussions, particularly concerning travel insurance. Failure to declare the use of weight-loss injections can invalidate insurance claims if a medical issue arises that is linked to the medication or its side effects. Insurance companies may deny coverage if a traveler experiences complications related to obesity, diabetes, or GLP-1 side effects, especially if the medication was not legally prescribed or disclosed.
Doctors and health professionals emphasize the critical importance of informing healthcare providers and loved ones about GLP-1 use. This ensures that medical professionals are aware of potential interactions and risks, particularly in emergency situations or before surgical procedures. Regulatory bodies like the MHRA have tightened controls on online pharmacies, requiring more rigorous selection processes, including video consultations and automatic GP notifications, making it more difficult for those who do not meet the strict BMI and health criteria to obtain prescriptions legally.